Skip to main content

Advertisement

Log in

Radioimmunotherapy of B-cell non-Hodgkin's lymphoma

  • Review Article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract.

In the past decade, several new antibody-based therapies – using either radiolabelled or unlabelled monoclonal antibodies – have become available for the treatment of patients with refractory or recurrent non-Hodgkin's lymphoma (NHL). Unlabelled monoclonal antibodies (mAbs) kill lymphoma cells by activating host immune effector mechanisms, or by inducing apoptosis. These mAbs can also be used to guide radionuclides to the lymphoma. This radioimmunotherapy (RIT) has been studied with various nuclides (131I, 90Y, 67Cu and 186Re) and with various mAbs. In this review the radionuclides, methods of dosing and recent RIT studies in patients with B-cell NHL are reviewed. Most of these studies demonstrate that RIT is an effective new treatment modality for NHL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Electronic Publication

Rights and permissions

Reprints and permissions

About this article

Cite this article

Postema, E.J., Boerman, O.C., Oyen, W.J. et al. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Eur J Nucl Med 28, 1725–1735 (2001). https://doi.org/10.1007/s002590100570

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002590100570

Navigation